An investigation of the constancy of effect in Cochrane systematic reviews in context with the assumptions for noninferiority trials
Abstract When designing a noninferiority (NI) study one of the most important steps is to set the noninferiority (NI) limit. The NI limit is an acceptable loss of efficacy for a new investigative treatment compared to an active control treatment – often standard care. The limit should be a value so...
Main Authors: | Enass M. Duro, Steven A. Julious, Shijie Ren |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-07-01
|
Series: | BMC Medical Research Methodology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12874-022-01684-9 |
Similar Items
-
Understanding superiority, noninferiority, and equivalence for clinical trials
by: Kamal Kishore, et al.
Published: (2020-01-01) -
Understanding noninferiority trials
by: Seokyung Hahn
Published: (2012-11-01) -
The normality assumption on between-study random effects was questionable in a considerable number of Cochrane meta-analyses
by: Ziyu Liu, et al.
Published: (2023-03-01) -
Key insights and challeneges in noninferiority trials
by: Boohwi Hong, et al.
Published: (2024-08-01) -
Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24‐week, randomized, double‐blind, active‐controlled, phase 3 trial
by: Lingding Xie, et al.
Published: (2024-04-01)